profit from every $100 of sales.
$0$100
Cellyan Biotechnology
$1.62+5.88% today
-93.1% in 1 year
1-year low $1.361-year high $24.00
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Cellyan Biotechnology sold, what it kept, and what it did with the cash.
Sales went from $12.6 million in 2023 to $20.3 million in 2025, with -$27,056 of profit last year.
SalesProfit
Cellyan Biotechnology vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Cellyan Biotechnology | No profit yet | ||
 Atai Beckley N.V | No profit yet | ||
 Avalyn Pharma | No profit yet | ||
 Cullinan Therapeutics | No profit yet | ||
 High Tide | No profit yet |
AI analysis
An AI analyst reads Cellyan Biotechnology's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| 13 | 17 | 20 | |
| 3 | 4 | 2 | |
| 1 | 2 | 0 | |
| 2 | 3 | 1 | |
| 1 | 1 | -0 | |
| 0.09 | 0.12 | -0.00 | |
| 21.8% | 21.3% | 11.9% | |
| 8.6% | 10.0% | 1.0% | |
| 7.9% | 8.0% | -0.1% |
Balance sheet
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total assets | 3 | 9 | 9 |
| Cash | 1 | 1 | 1 |
| Total debt | 1 | 2 | 2 |
| Total liabilities | 3 | 4 | 4 |
| 1 | 4 | 5 | |
| 11 | 11 | 10 | |
| 64.6% | 20.0% | 1.4% | |
| 170.6% | 31.3% | -0.5% |
Cash flow
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| 2 | -0 | 1 | |
| 0 | 0 | 0 | |
| 2 | -0 | 0 | |
| Dividends paid | – | – | – |
| – | – | – | |
| – | – | – |
Valuation
- –
- –
- –
- 1.1×
- 0.2×
- 9.6×
- 4.7×
- 10.4%
- -0.7%
- 0.0%
Profitability
- 11.9%
- 1.0%
- -0.1%
- 5.9%
- -1.3%
- 32.9%
- -0.6%
- -0.3%
- 2.0%
- –
Growth
- +27.2%
- –
- +185.9%
- –
- −9.4%
Financial health
- 1.3×
- 0.48
- 25.2%
- 1.4×
- 2.99
- 2.80
- 2.16
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 35%of 946
Bottom 30%of 872
Top 21%of 868
Top 7%of 986
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
55No pass
Benjamin Graham
64Pass
Philip Fisher
55No pass
Peter Lynch
74Pass
Joel Greenblatt
2No pass
Charlie Munger
53No pass
Terry Smith
52No pass
Questions about Cellyan Biotechnology
Is Cellyan Biotechnology a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Cellyan Biotechnology AI analysis
What does Cellyan Biotechnology do?
Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It is in Medical - Pharmaceuticals.
Does Cellyan Biotechnology pay a dividend?
No. Cellyan Biotechnology does not pay a dividend at the moment.
Is Cellyan Biotechnology stock halal?
No. Cellyan Biotechnology does not pass our halal screen: its debt is 60% of its market value, at or above the 33% limit. How we check
How has Cellyan Biotechnology stock done over the past year?
Down 93.1% over the past twelve months, to $1.62. It traded between $1.36 and $24.00 and is 93.3% below its high.
Who are Cellyan Biotechnology's competitors?
The largest listed companies in the same industry are Atai Beckley N.V, Avalyn Pharma, Cullinan Therapeutics and High Tide. The peers table on this page compares their profit, growth and price with Cellyan Biotechnology's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.